HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

1,557.889

+31.0702.03%

Number of Gainers:7

Number of Losers:8

Number of Flat:3

PE:- -

High:1,574.012

Open:1,526.678

Low:1,513.941

Close:1,526.819

Volume:746.51M

Turnover:8.88B

Market Cap:1.03T

Float Cap:872.46B

Loading ...

BYD Electronic (International) Stock Slides 2.0% in Hong Kong

ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs

CISI FIN Maintains "Buy" Rating on BYD ELECTRONIC (00285), Profitability Improves in 2025H1

Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug

MT Newswires Live

Hong Kong Stocks Movement | Most Internet Healthcare Stocks Rise as National Medical Products Administration Regulates Online Prescription Drug Retail, Institutions Recommend Focusing on Industry Recovery Opportunities

Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 9% as JS005 Achieves Positive Results in Phase III Clinical Trial for Moderate to Severe Plaque Psoriasis

BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind

Morgan Stanley Initiates Buy Rating on FOSUN PHARMA (02196) with A-Share Target Price of 42 RMB and H-Share Target Price of 33 HKD

SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection

Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind

THOMSON REUTERS

KINTOR PHARMA-B (09939): KT-939 Human Long-term Safety Trial Completes Full Subject Enrollment

Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939

Fosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial

MT Newswires Live

Executive Director Jiang Xiangrong Increases Holdings in BYD ELECTRONIC (00285) by 8,000 Shares at HK$41.9 Per Share

BYD Q2 Net Profit Plunges 30%: R&D Expenses Surge 50%, Gross Margin Continues Decline as Sales Inflection Point Looms with Volume-Price Double Drop Challenge

Fosun Pharma's (600196.SH) Subsidiary Henlius Receives US FDA Approval for HLX17 Clinical Trial

Hong Kong Stocks End in Green; Junshi Bio Gains 3%

MT Newswires Live

BYD Company Limited Sues Great Wall Motor's Tank CEO Chang Yao, Who Has Been Missing for Two Months; Court to Hold Hearing in Late September

Sino Biopharmaceutical Stock Advances 1.1% in Hong Kong

JD Health International Stock Falls 1.3% in Hong Kong

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":1557.8887,"timestamp":1757405290965,"preClose":1526.8188,"halted":0,"volume":746507675,"delay":0,"changeRate":0.020349,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":31.069824,"latestTime":"09-09 16:00:00","open":1526.6782,"high":1574.012,"low":1513.9413,"amount":8881416211,"amplitude":0.039344,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"pbRate":2.420622,"peRate":31.997398,"turnoverRate":0.009928,"increases":5,"decrements":10,"flats":2,"marketCap":1030672858624,"floatMarketCap":872462083456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":1574.012,"amplitude":0.039344,"preClose":1526.8188,"low":1513.9413,"pbRate":"2.420622","latestPrice":1557.8887,"volume":746507675,"delay":0,"open":1526.6782,"prevYearClose":787.97723,"prevWeekClose":1516.227,"prevMonthClose":1413.928,"prevQuarterClose":1028.719,"fiveDayClose":1473.257,"twentyDayClose":1291.398,"sixtyDayClose":1050.09,"secType":"PLATE","market":"HK","turnoverRate":0.009928,"peRate":31.997398,"marketCap":1030672858624,"floatMarketCap":872462083456,"timestamp":1757405290965,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":7,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566466712","title":"BYD Electronic (International)  Stock Slides 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2566466712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566466712?lang=en_us&edition=fundamental","pubTime":"2025-09-09 16:33","pubTimestamp":1757406780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. slipped 2.0% to 42.12 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 25938.13.The stock's fall snapped a three-day winning streak.BYD Electronic  Co. Ltd. closed 32% below its 52-week high of HK$61.55, which the company achieved Feb. 13.The stock underperformed when compared to some of its competitors, as Times Universal Group Holdings Ltd. remained unchanged.Trading volume totaled 21.6 million shares, compared to the 50-day average of 29.8 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00285","LU0348766576.USD","BK1540","BK1580","BK1582","LU0348767384.USD","BK1149","BK1504","BK1589","LU0274383008.USD","BK1607"],"gpt_icon":1},{"id":"1126765801","title":"ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1126765801","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126765801?lang=en_us&edition=fundamental","pubTime":"2025-09-09 12:20","pubTimestamp":1757391650,"startTime":"0","endTime":"0","summary":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion. HSBC Global Research noted that health products are expected to continue being...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1142","BK1615","BK1589","BK1502","BK1247","BK1501","BK1189","BK1584","BK1591","BK1515","BK1571","BK1610","00241","BK1617"],"gpt_icon":1},{"id":"1146069463","title":"CISI FIN Maintains \"Buy\" Rating on BYD ELECTRONIC (00285), Profitability Improves in 2025H1","url":"https://stock-news.laohu8.com/highlight/detail?id=1146069463","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146069463?lang=en_us&edition=fundamental","pubTime":"2025-09-09 11:42","pubTimestamp":1757389351,"startTime":"0","endTime":"0","summary":"CISI FIN issued a research report maintaining a \"buy\" rating on BYD ELECTRONIC (00285), projecting the company's revenue for 2025-2027 at RMB 189.5/205.8/223.3 billion respectively, with net profit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1582","LU0348766576.USD","LU0348767384.USD","BK1504","BK1149","BK1515","06058","BK1580","00285","LU0274383008.USD","BK1540","BK1589","BK1607","BK1147","BK1564"],"gpt_icon":1},{"id":"2566652502","title":"Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2566652502","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566652502?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:31","pubTimestamp":1757385061,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical  said Chinese regulators approved its experimental P052 injection for human studies, according to a Hong Kong bourse filing Tuesday.The company is developing P052 as a treatment for type 2 diabetes and obesity.The drug has a mechanism similar to Novo Nordisk's semaglutide.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"1111009005","title":"Hong Kong Stocks Movement | Most Internet Healthcare Stocks Rise as National Medical Products Administration Regulates Online Prescription Drug Retail, Institutions Recommend Focusing on Industry Recovery Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1111009005","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111009005?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:22","pubTimestamp":1757384544,"startTime":"0","endTime":"0","summary":"Most internet healthcare stocks posted gains during trading. As of press time, DINGDANG HEALTH (09886) surged 8.54% to HK$0.89; ALI HEALTH (00241) climbed 6.16% to HK$6.89; FANGZHOU JIANKE (06086)...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1502","BK1617","BK1501","BK1583","09886","00241","BK1584","BK1589","BK1515","06618","86618","BK1610","BK1571","LU0051755006.USD","BK1189","BK1615","BK1247","BK1591","06086","LU0456827905.SGD","BK1142"],"gpt_icon":1},{"id":"1161833173","title":"Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 9% as JS005 Achieves Positive Results in Phase III Clinical Trial for Moderate to Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=1161833173","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161833173?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:02","pubTimestamp":1757383338,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged over 9%, and as of press time, the stock was up 8.36% to HK$38.36 with a turnover of HK$173 million. On the news front, JUNSHI BIO announced that its recombinant humanized...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1583","BK0239","BK1161","688180","BK1515"],"gpt_icon":0},{"id":"2566965651","title":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566965651","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566965651?lang=en_us&edition=fundamental","pubTime":"2025-09-09 09:33","pubTimestamp":1757381597,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For IndSept 9 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:P052 INJECTION INDEPENDENTLY DEVELOPED BY HUISHENG BIOPHARMACEUTICAL APPROVED FOR INDFurther company coverage: 0460.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","00460","BK1191","BK1593"],"gpt_icon":0},{"id":"1153469279","title":"Morgan Stanley Initiates Buy Rating on FOSUN PHARMA (02196) with A-Share Target Price of 42 RMB and H-Share Target Price of 33 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1153469279","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153469279?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:34","pubTimestamp":1757378072,"startTime":"0","endTime":"0","summary":"According to recent reports, international investment bank Morgan Stanley has released a latest research report stating that FOSUN PHARMA (600196.SH, 02196) is demonstrating improving profitability...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0196","BK0012","BK0183","02196","BK0188","BK1191","600196","BK0175","BK0239","BK1515","159982","BK0187","BK0060","BK1593","399300","BK0028"],"gpt_icon":0},{"id":"1131898226","title":"SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1131898226","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131898226?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:16","pubTimestamp":1757376982,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd. (Huisheng Bio), has received tacit approval from the Center for Drug Evaluation (CDE) of the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","06978","BK1574","BK1515","BK1593","BK4590","BK1600","GLP","159992","BK4144","00460"],"gpt_icon":0},{"id":"2566653655","title":"Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566653655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566653655?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:02","pubTimestamp":1757376174,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1191","BK1515","00460","BK1600"],"gpt_icon":0},{"id":"1156364553","title":"KINTOR PHARMA-B (09939): KT-939 Human Long-term Safety Trial Completes Full Subject Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1156364553","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156364553?lang=en_us&edition=fundamental","pubTime":"2025-09-09 06:20","pubTimestamp":1757370026,"startTime":"0","endTime":"0","summary":"KINTOR PHARMA-B (09939) announced that its independently developed novel high-efficiency tyrosinase inhibitor KT-939, which inhibits melanin production, has recently completed enrollment of all 130...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0541501648.USD","LU0541502299.USD","BK1515","KT","09939","BK1161","BK4115"],"gpt_icon":0},{"id":"2566630254","title":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939","url":"https://stock-news.laohu8.com/highlight/detail?id=2566630254","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566630254?lang=en_us&edition=fundamental","pubTime":"2025-09-09 06:12","pubTimestamp":1757369567,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939. Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL4TRbDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1574","BK1161"],"gpt_icon":0},{"id":"2565689357","title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2565689357","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565689357?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:58","pubTimestamp":1757332735,"startTime":"0","endTime":"0","summary":"A unit of Shanghai Fosun Pharmaceutical  unit obtained approval from China's National Medical Products Administration for the clinical trial of Foritinib Succinate Capsules, a Monday Hong Kong bourse filing said.The trial will study the drug for adjuvant treatment following the radical resection of tumor in patients with stage IB to IIIA non-small cell lung cancer.Unit Fosun Wanbang  Pharmaceutical Group will begin the phase III trial of the drug once the relevant conditions are met.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK0196","BK0175","BK0096","BK0187","BK1515","BK1191","BK0188","BK1593","00656","BK0012","BK0183","600196","BK0028","02196"],"gpt_icon":0},{"id":"1178464452","title":"Executive Director Jiang Xiangrong Increases Holdings in BYD ELECTRONIC (00285) by 8,000 Shares at HK$41.9 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1178464452","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178464452?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:20","pubTimestamp":1757330443,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on September 5, Executive Director Jiang Xiangrong increased his holdings in BYD ELECTRONIC (00285) by 8,000 shares at HK$41.9 per share, with a total value of HK$335,200. His latest shareholding stands at 270,000 shares.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU0348766576.USD","LU0348767384.USD","00285","BK1540","BK1515","BK1504","BK1580","BK1149","LU0274383008.USD","BK1607","BK1582"],"gpt_icon":0},{"id":"1139539147","title":"BYD Q2 Net Profit Plunges 30%: R&D Expenses Surge 50%, Gross Margin Continues Decline as Sales Inflection Point Looms with Volume-Price Double Drop Challenge","url":"https://stock-news.laohu8.com/highlight/detail?id=1139539147","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139539147?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:11","pubTimestamp":1757329905,"startTime":"0","endTime":"0","summary":"BYD Company Limited recently released its 2025 interim report. In the first half of this year, the company achieved operating revenue of 371.281 billion yuan, a year-on-year increase of 23.30%, and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU2357125470.USD","LU0259732245.USD","HYDD.SI","LU0509642566.USD","LU1720050803.USD","LU0823426308.USD","LU0449515922.USD","BK1515","LU0683595622.HKD","LU0463099449.HKD","LU2097828714.EUR","LU1242518857.USD","LU2476274720.SGD","LU0634319403.HKD","LU2097828805.USD","LU0561508036.HKD","LU0594300419.USD","LU2449936058.SGD","LU0505663152.USD","LU2148510915.USD","LU2097828474.EUR","LU2289578879.USD","LU1861214812.USD","BK0155","BK0072","BK1540","LU0175139822.USD","SG9999006514.SGD","BK1594","LU1328277881.USD","LU0315178854.USD","LU0164872284.USD","LU0588545730.USD","LU1242518931.SGD","LU0417516902.SGD","LU2580892789.USD","LU2778985437.USD","LU0417516738.SGD","SG9999015952.SGD","LU0828238088.HKD","LU2476274308.USD","BK1589","LU1868838027.USD","LU0244354667.USD","LU1997245094.SGD","LU0856984785.SGD","LU1719994722.HKD","LU1880383440.USD","LU0650527681.SGD","LU0327786744.USD","LU1868837565.USD","LU1303224171.USD","LU0348735423.USD","LU2495084118.USD","LU2506951792.HKD","LU2328871848.SGD","LU0819121731.USD","BYDDY","LU0823426480.USD","LU1794554557.SGD","LU1813983027.USD","SG9999006597.SGD","LU0871576103.HKD","SG9999015978.USD","LU0348827113.USD","LU1880383366.USD","BK1149","LU1508157978.USD","LU1188198961.HKD","LU1770034418.SGD","LU0819123356.HKD","LU0326950275.SGD","SG9999002463.SGD","BK0169","LU0320764599.SGD","LU2097828631.EUR","LU0594300179.USD","LU2249611893.SGD","01211","LU0516423091.SGD","LU2360107325.USD","BK1119","LU0143863198.USD","LU0516422952.EUR","LU0588546209.SGD","00285","LU0516422440.USD","LU2153592121.USD","LU0511384066.AUD","LU0229945570.USD","LU0348805143.USD","IE00BD6J9T35.USD","LU1146622755.USD","LU0214875030.USD","LU1997244956.HKD","LU1781817850.SGD","LU2294711713.HKD","LU0164865239.USD","LU0865486749.SGD","LU0823039010.USD","LU0269904917.USD","LU0348767384.USD","LU0572944931.SGD","LU0531971595.HKD","LU2039709279.SGD","SG9999014674.SGD","LU0979878070.USD","LU0593848301.USD","LU0084288322.USD","LU0359201612.USD","LU0605514214.HKD","LU0211977185.USD","BK0196","LU1251922891.USD","LU1861219969.SGD","LU0143863784.USD","LU0052750758.USD","LU0588545490.SGD","LU0708995583.HKD","LU1820825898.SGD","LU0588545904.SGD","LU2097828557.USD","BK1580","BK1504","LU0516423174.USD","SG9999015945.SGD","BK1539","LU0289961442.SGD","LU1961090484.USD","LU0823414551.USD","LU0039217434.USD","LU0274383008.USD","LU0633140727.USD","LU1064131003.USD","LU1580142542.USD","LU0348825331.USD","LU1808992512.USD","SG9999002828.SGD","LU0633140560.USD","LU1868837722.USD","BK0070","BK1610","LU0054450605.USD","LU0348766576.USD","BK1582","LU2580892862.HKD","LU2399975544.HKD","LU0359202008.SGD","BK1522","LU0540923850.HKD","LU0823038988.USD","BK0014","002594","BK1509","BK1607","LU0516422366.SGD","LU0254981946.USD","SG9999015986.USD","EVS.SI","LU0469268626.HKD","LU0165289439.USD","LU0307460666.USD","LU0823414478.USD","LU0359201885.HKD","BK0188","LU0314109678.HKD","LU2663582299.SGD","LU1969619763.USD","LU1064130708.USD","LU1023057109.AUD","LU0543330566.HKD","LU0043850808.USD","81211","LU2348774022.SGD","SG9999001226.SGD","LU1997245177.USD","LU0531970944.HKD","LU0449509016.USD","BK0183","BK0264","LU0289960550.SGD"],"gpt_icon":1},{"id":"1174416304","title":"Fosun Pharma's (600196.SH) Subsidiary Henlius Receives US FDA Approval for HLX17 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1174416304","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174416304?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:16","pubTimestamp":1757326598,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its controlled subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively \"Henlius\") recently...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK0096","BK0188","BK0187","BK0028","BK1161","BK1515","BK0060","BK0175","BK1593","BK0239","BK1191","BK0196","BK0012","02196","600196","BK0183"],"gpt_icon":0},{"id":"2565504344","title":"Hong Kong Stocks End in Green; Junshi Bio Gains 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565504344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565504344?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:43","pubTimestamp":1757321007,"startTime":"0","endTime":"0","summary":"Hong Kong stocks ended higher Monday as markets analyzed the latest trade data from China and investors factored in a chance of a major rate cut in the U.S.The Hang Seng Index gained 215.93 points, or 0.9%, to 25,633.91, while the Hang Seng China Enterprises Index rose 64.44 points, or 0.71%, to 9,121.66.China's exports jumped by 4.4% in August, while imports rose by 1.3%, according to official data. The figures missed the respective 5% and 3% growth predicted by analysts polled by Reuters.Meanwhile, markets increasingly expected the Federal Open Market Committee to cut rates next week after the U.S. reported dismal labor data, Reuters reported.In corporate news, Hesai Group  launched its initial public offering in Hong Kong, seeking to raise as much as HK$3.88 billion from the deal.The three-dimensional light detection developer is offering up to 17 million shares at an indicative price of HK$228.00 apiece, according to an filing with the Hong Kong Exchange.Elsewhere, Shanghai Junshi ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HHImain","MCHmain","HSI","BK1515","513600","BK0239","BK1161","BK1583","01877","MHImain","02525","02833","688180"],"gpt_icon":0},{"id":"1101541753","title":"BYD Company Limited Sues Great Wall Motor's Tank CEO Chang Yao, Who Has Been Missing for Two Months; Court to Hold Hearing in Late September","url":"https://stock-news.laohu8.com/highlight/detail?id=1101541753","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101541753?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:41","pubTimestamp":1757320895,"startTime":"0","endTime":"0","summary":"On September 8, the People's Court Announcement Network published a notice that BYD Company Limited (002594.SZ) has filed a lawsuit against Chang Yao for online infringement liability disputes, with...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0633140560.USD","SG9999014674.SGD","LU0531970944.HKD","BK1522","SG9999006597.SGD","LU0823414478.USD","LU0516423091.SGD","002594","LU0819123356.HKD","LU1880383440.USD","LU2580892862.HKD","BK1580","LU1242518931.SGD","LU2097828474.EUR","LU0289960550.SGD","LU0348827113.USD","BK1594","LU2097828714.EUR","LU0572944931.SGD","LU0588545904.SGD","LU2039709279.SGD","LU0865486749.SGD","LU2506951792.HKD","LU0633140727.USD","LU0143863784.USD","LU0175139822.USD","LU2294711713.HKD","LU0979878070.USD","LU1969619763.USD","SG9999015945.SGD","LU0505663152.USD","LU1719994722.HKD","LU2476274720.SGD","SG9999015952.SGD","LU1580142542.USD","LU0683595622.HKD","SG9999002463.SGD","LU1997245177.USD","LU0823414551.USD","LU2449936058.SGD","LU1064131003.USD","SG9999001226.SGD","EVS.SI","LU0289739343.SGD","LU0307460666.USD","LU1251922891.USD","LU1328277881.USD","LU0823039010.USD","LU0588545730.USD","LU2495084118.USD","LU0348766576.USD","LU0588546209.SGD","LU0327786744.USD","SG9999015978.USD","LU0359201612.USD","LU0269904917.USD","BK1607","LU0543330566.HKD","BK1582","LU2476274308.USD","LU0164865239.USD","LU1808992512.USD","BK1119","LU0348767384.USD","LU2778985437.USD","LU0531971595.HKD","LU0463099449.HKD","LU0164872284.USD","LU1813983027.USD","BK1504","BK1515","LU1861214812.USD","SG9999006514.SGD","LU0348805143.USD","LU0871576103.HKD","BK0014","LU1861219969.SGD","LU0708995583.HKD","LU1720050803.USD","BK0264","BK1509","LU0084288322.USD","LU0314109678.HKD","LU0214875030.USD","LU0326950275.SGD","IE00BD6J9T35.USD","LU0828238088.HKD","LU0823426480.USD","LU1794554557.SGD","LU1188198961.HKD","LU2097828805.USD","BK0072","LU1146622755.USD","LU0540923850.HKD","LU2097828631.EUR","BK0196","BK1540","LU0320764599.SGD","LU0449509016.USD","LU0819121731.USD","LU0823426308.USD","LU1023057109.AUD","BK1149","LU0509642566.USD","02333","LU0561508036.HKD","LU0511384066.AUD","BK0169","LU0417516902.SGD","SG9999015986.USD","LU1820825898.SGD","LU1770034418.SGD","GWLLY","LU2153592121.USD","LU2148510915.USD","LU0043850808.USD","LU0274383008.USD","LU0165289439.USD","BK0155","LU1880383366.USD","LU0516422952.EUR","LU1997244956.HKD","LU0634319403.HKD","LU0052750758.USD","LU1781817850.SGD","81211","BK1589","LU1961090484.USD","LU0449515922.USD","00285","LU0359201885.HKD","LU0605514214.HKD","BK0188","LU0856984785.SGD","LU0054450605.USD","LU0244354667.USD","BK1610","LU0823038988.USD","LU1064130708.USD","LU2097828557.USD","BK1539","LU0650527681.SGD","LU1868837565.USD","LU2580892789.USD","SG9999002828.SGD","LU0469268626.HKD","LU0593848301.USD","LU0359202008.SGD","LU2360107325.USD","LU0348735423.USD","LU0315178854.USD","LU1868838027.USD","LU2399975544.HKD","LU0348825331.USD","LU0516422440.USD","LU2249611893.SGD","LU0417516738.SGD","LU0211977185.USD","LU0143863198.USD","LU2289578879.USD","LU0594300179.USD","LU0289961442.SGD","LU0516423174.USD","LU2663582299.SGD","LU0039217434.USD","LU2357125470.USD","82333","BK0183","BYDDY","LU0229945570.USD","LU1997245094.SGD","LU0588545490.SGD","HYDD.SI","LU1303224171.USD","601633","LU1242518857.USD","LU1508157978.USD","LU2348774022.SGD","01211","BK0070","LU0254981946.USD","LU0594300419.USD","LU0516422366.SGD","LU1868837722.USD","LU2328871848.SGD","LU0259732245.USD"],"gpt_icon":1},{"id":"2565501190","title":"Sino Biopharmaceutical Stock Advances 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2565501190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565501190?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:33","pubTimestamp":1757320380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 1.1% to 9.01 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.8% to 25633.91.This was the stock's second consecutive day of gains.Sino Biopharmaceutical Ltd. hit a new 52-week high, surpassing its previous peak of HK$8.99, which the company achieved Sept. 5.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 2.6% and Amgen Inc. fell 4.8%.Trading volume totaled 120.9 million shares, compared to the 50-day average of 178.3 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1589","IE00BZ08YR35.GBP","BK1191","BK1515","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2565011455","title":"JD Health International Stock Falls 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2565011455","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565011455?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:33","pubTimestamp":1757320380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. slid 1.3% to 63.05 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.8% to 25633.91.This was the stock's second consecutive day of losses.JD Health International Inc. closed 9.1% short of its 52-week high of HK$69.35, which the company reached Aug. 19.Trading volume totaled 13.1 million shares, compared to the 50-day average of 10.2 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06618","BK1583","86618","BK1591","BK1142","BK1247","BK1571","BK1615","LU0456827905.SGD","BK1589","LU0051755006.USD","BK1515"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":182,"code":"91000000","status":"200"}]}}